| アブストラクト | INTRODUCTION: Mortality rates from various cancer types are higher in patients with hyperglycaemia-associated pathologies. Among antineoplastics for treating pancreatic carcinoma, doxorubicin was found to be top of the list for inducing hyperglycaemia-related adverse drug reactions. METHODS: Individual case safety reports of doxorubicin-induced hyperglycaemia-related adverse drug reactions (HG-ADRs) submitted during the period 2000-2017 were extracted from VigiBase((R)). Factors influencing outcome seriousness in these cases were analyzed using bivariate correlation and logistical regression. Age was stratified into five groups. RESULTS: Among the 558 cases with high blood glucose included in this study, with an average patient age of 55.9 +/- 14.3 years, 71.1% had serious outcomes and 10.9% died. Three factors-died, age, and gender-were all found to be significantly correlated with outcome seriousness (P < 0.01), while five factors-year reported, ADR duration, latency, treatment duration, and dosage-showed no correlation with outcome seriousness (P > 0.05). Identical conclusions were reached upon analyzing only the cases that did not involve corticosteroid use. CONCLUSION: Age and gender are risk factors for doxorubicin-induced serious HG-ADRs; males and older patients are more likely to suffer a serious outcome following such a reaction. |
|---|
| ジャーナル名 | Diabetes therapy : research, treatment and education of diabetes and related disorders |
|---|
| Pubmed追加日 | 2019/8/21 |
|---|
| 投稿者 | Yang, Jincheng; Wang, Yu; Liu, Kang; Yang, Wen; Zhang, Jianying |
|---|
| 組織名 | Department of Pharmacy, National Cancer Center/National Clinical Research Center;for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union;Medical College, Beijing, China. Yangjc@cicams.ac.cn.;Medical College, Beijing, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/31428942/ |
|---|
